Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Maternal Blood Test Detects Pre-Eclampsia Risk Before Symptoms Develop

By LabMedica International staff writers
Posted on 19 Nov 2025

Pre-eclampsia remains one of the most dangerous pregnancy complications, yet its cause is difficult to pinpoint because the disorder develops silently and is challenging to study. More...

A major obstacle has been identifying early molecular signals that warn of risk before symptoms appear. Researchers have now discovered that ancient viral DNA embedded in the human genome helps control a placenta-related gene that, when overexpressed, triggers key features of pre-eclampsia, pointing to a potential early biomarker for the condition.

In research led by the Max Delbrück Center (Berlin, Germany) and the University of Bath (Bath, England), the team used advanced deep-learning tools and biological assays to investigate how endogenous viral DNA fragments regulate placental gene expression. The method focused on A100 Beast, a deep-learning model created in the Mobile DNA Lab at the Max Delbrück Center.

By training the AI model to interpret DNA “like language,” researchers classified regulatory sequences across species and uncovered previously overlooked enhancers — many derived from ancient viruses. In placental genomes, the model identified a cluster of ERV3-MLT1 viral enhancers that appeared unusually active. Follow-up analyses confirmed 87 virus-derived enhancers in human placental tissue, boosting nine genes commonly dysregulated in pre-eclampsia.

Experimental work then focused on one gene in particular: EPS8L1, a previously unstudied gene expressed in trophoblasts, the early placental cells essential for implantation and placental formation. Functional studies exposed the gene’s role in disease: overexpressing EPS8L1 in placental cell cultures induced hallmark features of pre-eclampsia, including diminished trophoblast invasion, impaired blood vessel formation, and oxidative stress–related cell damage. Complete knockout of the gene caused cell death, confirming its necessity for normal placental function.

A key practical finding was that a secreted form of EPS8L1 is detectable in maternal blood, where its levels tracked with known pre-eclampsia biomarkers. The gene was consistently upregulated across all study cohorts and did not appear in other pregnancy complications, suggesting it could serve as a specific early-onset biomarker for pre-eclampsia if validated in larger clinical studies.

In addition to its diagnostic potential, the research, published in Genome Biology, highlights the deep evolutionary roots of this regulatory system. The ERV3-MLT1 viral DNA driving EPS8L1 expression originated more than 100 million years ago in a common ancestor of primates and rodents, illustrating how ancient viral infections still shape modern human biology.

“These findings connect a deep evolutionary process to a very modern clinical problem and point to a potential biomarker to detect pre-eclampsia risk before symptoms develop,” said Professor Zsuzsanna Izsvák, group leader and co-corresponding author.

Related Links:
Max Delbrück Center
University of Bath


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.